Estimating the economic value to societies of the impact of health research: A critical review

Bulletin of the World Health Organization

Volumn 82, Issue 10, 2004, Pages 733-739

  Buxton, Martin ^a   Hanney, Steve ^a   Jones, Teri ^a  

^a BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

Cost savings; Cost benefit analysis; Delivery of health care economics; Economic development; Health services research economics; Longevity; Review literature

Indexed keywords

DISEASE TREATMENT; ECONOMIC IMPACT; HEALTH CARE; HUMAN CAPITAL; RESEARCH;

CAPITAL; COST BENEFIT ANALYSIS; COST CONTROL; DEVELOPED COUNTRY; DEVELOPING COUNTRY; ECONOMIC EVALUATION; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH CARE SYSTEM; HEALTH ECONOMICS; INVESTMENT; MEDICAL RESEARCH; METHODOLOGY; REVIEW; SOCIAL PSYCHOLOGY; SOCIETY;

BIOMEDICAL RESEARCH; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HEALTH POLICY; HEALTH SERVICES RESEARCH; HEALTH STATUS; HUMANS; INVESTMENTS; LONGEVITY; PUBLIC HEALTH ADMINISTRATION; RESEARCH SUPPORT; SOCIAL VALUES;

EID: 7644239880     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Mexico, 2004: Research for global health and security. Lancet 2003;362:2033.
2. Pang T, Sadana R, Hanney S, Bhutta Z, Hyder A, Simon J. Knowledge for better health - a conceptual framework and foundation for health research systems. Bulletin of the World Health Organization 2003;81:815-20.
3. Hanney S, Gonzalez-Block M, Buxton M, Kogan M. The utilisation of health research in policy-making: concepts, examples and methods of assessment. Health Research Policy and Systems 2003;1:2. Available from http://www.health-policy- systems.com/content/1/1/2
4. Buxton M, Hanney S. How can payback from health services research be assessed? Journal of Health Services Research & Policy 1996;1:35-43.
5. Investing in health research for development. Report of the Ad Hoc Committee on Health Research Relating to Future Intervention Options. Geneva: World Health Organization; 1996.
6. Office of Technology Assessment. Research funding as an investment: can we measure the retums? A technical memorandum. Washington (DC): Office of Technology Assessment, United States Government Printing Office; 1986.
7. Sen A. Development as freedom. New York: Oxford University Press; 1999.
8. Townsend J, Buxton M, Harper G. Prioritisation of health technology assessment. The PATHS model: methods and case studies. Health Technology Assessment 2003;7.
9. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001.
10. The world health report 2002 - reducing risks, promoting healthy life. Geneva: World Health Organization; 2002.
11. Sawert H, Kongsin S, Payanandana V, Akarasewi P, Nunn P, Raviglione M. Costs and benefits of improving tuberculosis control: the case of Thailand. Social Science and Medicine 1997;44:1805-16.
12. Cozzens S. The knowledge pool: measurement challenges in evaluating fundamental research programs. Evaluation and Program Planning 1997;20:77-89.
13. Cockburn I, Henderson R. Public-private interaction and the productivity of pharmaceutical research. NBER Working Paper Series. Cambridge, Massachusetts: National Bureau of Economic Research; 1997 (Report No. 601.)
14. Comroe J, Dripps R. Scientific basis for the support of biomedical science. Science 1976;192:105-11.
15. Raiten D, Berman S. Can the impact of basic biomedical research be measured?: A case study approach. Bethesda (MD): Life Sciences Research Office, FASEB; 1993.
16. McKeown T. The role of medicine. Oxford: Basil Blackwell; 1979.
17. Mushkin S. Biomedical research: costs and benefits. Cambridge (MA): Ballinger Publishing Company; 1979.
18. Morel C. Chagas disease, from discovery to control - and beyond: history, myths and lessons to take home. Memorias do Instituto Oswaldo Cruz 1999;94:3-16.
19. Fudenberg H, editor. Biomedical institutions, biomedical funding and public policy. New York: Plenum Press; 1983.
20. Weisbrod B. Economics and medical research. Washington: American Enterprise Institute for Public Policy Research; 1983.
21. Weisbrod B. Costs and benefits of medical research: a case study of poliomyelitis. Journal of Political Economy 1971;79:527-44.
22. Silverstein S, Garrison H, Heinig S. A few basic economic facts about research in the medical and related life sciences. FASEB Journal 1995;9:833-40.
23. Kirschner M, Marincola E, Teisberg E. The role of biomedical research in health care reform. Science 1994;266:49-51.
24. Davy G. Bioscience research, development and industry: impact on health and economic growth in wisconsin. Madison/Milwaukee: Wisconsin Association for Biomedical Research & Education; 1996. Available from http://www.wabre.org/ report_one/index.html
25. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Memorias do Instituto Oswaldo Cruz 2003;98:77-591.
26. Council for Scientific Policy. Second report on science policy. London: Her Majesty's Stationery Office; 1967.
27. Afseth J. On the value of research in health care. European Journal of Oral Sciences 1997;105:454-6.
28. Jacob R, McGregor M. Assessing the impact of health technology assessment. International Journal of Technology Assessment in Health Care 1997;13:68-80.
29. National Institutes of Health. Cost savings resulting from NIH research support. 2nd ed. Bethesda: United States Department of Health and Human Services, National Institutes of Health; 1993.
30. Drummond M, Davies L, Ferris F. Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine 1992;34:973-81.
31. Australian Society for Medical Research. Australian case studies, series I & II. Sydney: Australian Society for Medical Research; 2003, Available from http://www.asmr.org.au/news/
32. Mitchell P, Hadzi-Pavlovic D. Lithium treatment for bipolar disorder. Bulletin of the World Health Organization 2000;78:515-20.
33. Access Economics. Exceptional returns: The value of investing in health R&D Australia. Canberra: Access Economics; 2003.
34. Salter A, Martin B. The economic benefits of publicly funded basic research: a critical review. Research Policy 2001;30:509-32.
35. Mansfield E. Academic research and industrial innovation. Research Policy 1991;20:1-12.
36. Mansfield E. Academic research and industrial innovation: an update of empirical findings. Research Policy 1998;26:773-6.
37. Joint Economic Committee, United States Senate. The benefits of medical research and the role of the NIH. Washington (DC): Government Printing Office; 2000.
38. Pardes H, Manton K, Lander E, Tolley H, Ullian A, Palmer H. Effects of medical research on health care and the economy. Science 1999;283:36-7.
39. Rosenberg L. Exceptional economic returns on investments in medical research. Medical Journal of Australia 2002;177:368-71.
40. Gadelha C. Vaccine research, development and production in Brazil. Lessons in research to action and policy. Geneva: COHRED Working Group on Research to Action and Policy; 2000.
41. Kettler H, Modi R. Building local research capacity for the prevention and cure of neglected diseases: the case of India. Bulletin of the World Health Organization 2001;79:742-7.
42. Funding First. Exceptional returns: The economic value of America's investment in medical research. New York; 2000.
43. Murphy K, Topel R, editors. Measuring the gains from medical research. An economic approach. Chicago: The University of Chicago Press; 2003.
44. Nordhaus W. The health of nations: the contribution of improved health to living standards. In: Murphy K, Topel R, editors. Measuring the gains from medical research. An economic approach. Chicago: The University of Chicago Press; 2003. p. 9-40.
45. Murphy K, Topel R. The economic value of medical research. In: Murphy K, Topel R, editors. Measuring the gains from medical research. An economic approach. Chicago: The University of Chicago Press; 2003. p, 41-73.
46. Lichtenberg F. Pharmaceutical innovation, mortality reduction and economic growth. In: Murphy K, Topel R, editors. Measuring the gains from medical research. An economic approach. Chicago: The University of Chicago Press; 2003. p. 74-109.
47. Cutler D, Kadiyala S. The return to biomedical research: Treatment and behavioral effects. In: Murphy K, Topel R, editors. Measuring the gains from medical research. An economic approach. Chicago: The University of Chicago Press; 2003. p. 110-62.
48. Heidenreich P, McClellan M. Biomedical research and then some: The causes of technological change in heart attack treatment. In: Murphy K, Topel R, editors. Measuring the gains from medical research. An economic approach. Chicago: The University of Chicago Press; 2003. p. 163-205.
49. Aikins M, Fox-Rushby J, D'Alessandro U, Langerock P, Cham K, New L, et al. The Gambian National Impregnated Bednet Programme: costs, consequences and net cost-effectiveness. Social Science and Medicine 1998;46:181-91.
50. Utzinger J, Tozan Y, Doumani F, Singer B. The economic payoffs of integrated malaria control in the Zambian copperbelt between 1930 and 1950. Tropical Medicine and International Health 2002;7:657-77.